258 related articles for article (PubMed ID: 8895830)
41. Emerging filoviral disease in Uganda: proposed explanations and research directions.
Polonsky JA; Wamala JF; de Clerck H; Van Herp M; Sprecher A; Porten K; Shoemaker T
Am J Trop Med Hyg; 2014 May; 90(5):790-793. PubMed ID: 24515940
[TBL] [Abstract][Full Text] [Related]
42. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
[TBL] [Abstract][Full Text] [Related]
43. [Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects].
Hirabayashi Y
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):85-9. PubMed ID: 10088344
[No Abstract] [Full Text] [Related]
44. Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays.
Kamata T; Natesan M; Warfield K; Aman MJ; Ulrich RG
Clin Vaccine Immunol; 2014 Dec; 21(12):1605-12. PubMed ID: 25230936
[TBL] [Abstract][Full Text] [Related]
45. Ebola virus ecology: a continuing mystery.
Feldmann H; Wahl-Jensen V; Jones SM; Ströher U
Trends Microbiol; 2004 Oct; 12(10):433-7. PubMed ID: 15381189
[No Abstract] [Full Text] [Related]
46. Emerging and reemerging of filoviruses.
Feldmann H; Slenczka W; Klenk HD
Arch Virol Suppl; 1996; 11():77-100. PubMed ID: 8800808
[TBL] [Abstract][Full Text] [Related]
47. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses.
Mohamadzadeh M; Coberley SS; Olinger GG; Kalina WV; Ruthel G; Fuller CL; Swenson DL; Pratt WD; Kuhns DB; Schmaljohn AL
J Virol; 2006 Jul; 80(14):7235-44. PubMed ID: 16809329
[TBL] [Abstract][Full Text] [Related]
48. An update on the use of antibodies against the filoviruses.
Saphire EO
Immunotherapy; 2013 Nov; 5(11):1221-33. PubMed ID: 24188676
[TBL] [Abstract][Full Text] [Related]
49. [Stabilization of peroxidase conjugates used in enzyme immunoassay systems to detect Ebola and Marburg virus antigens].
Pirozhkov AP; Borisevich IV; Snetkova OIu; Androshchuk IA; Syromiatnikova SI; Khmelev AL; Shatokhina IV; Kudrin VIu; Timofeev MA; Pantiukhov VB; Borisevich SV; Markov VI; Bondarev VP
Vopr Virusol; 2010; 55(1):45-8. PubMed ID: 20364672
[TBL] [Abstract][Full Text] [Related]
50. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.
Grant-Klein RJ; Altamura LA; Schmaljohn CS
Virus Res; 2011 Dec; 162(1-2):148-61. PubMed ID: 21925552
[TBL] [Abstract][Full Text] [Related]
51. Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice.
Lavender KJ; Williamson BN; Saturday G; Martellaro C; Griffin A; Hasenkrug KJ; Feldmann H; Prescott J
J Infect Dis; 2018 Nov; 218(suppl_5):S409-S417. PubMed ID: 30085162
[TBL] [Abstract][Full Text] [Related]
52. Knowledge and attitude towards Ebola and Marburg virus diseases in Uganda using quantitative and participatory epidemiology techniques.
Nyakarahuka L; Skjerve E; Nabadda D; Sitali DC; Mumba C; Mwiine FN; Lutwama JJ; Balinandi S; Shoemaker T; Kankya C
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005907. PubMed ID: 28892520
[TBL] [Abstract][Full Text] [Related]
53. Drug targets in infections with Ebola and Marburg viruses.
Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
[TBL] [Abstract][Full Text] [Related]
54. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.
Warfield KL; Olinger GG
J Biomed Biotechnol; 2011; 2011():984241. PubMed ID: 22253531
[TBL] [Abstract][Full Text] [Related]
55. Broad and Temperature Independent Replication Potential of Filoviruses on Cells Derived From Old and New World Bat Species.
Miller MR; McMinn RJ; Misra V; Schountz T; Müller MA; Kurth A; Munster VJ
J Infect Dis; 2016 Oct; 214(suppl 3):S297-S302. PubMed ID: 27354372
[TBL] [Abstract][Full Text] [Related]
56. [Viral hemorrhagic fever--Ebola hemorrhagic fever, Marburg disease and Lassa fever].
Hotta H
Rinsho Byori; 1998 Jul; 46(7):651-5. PubMed ID: 9721531
[TBL] [Abstract][Full Text] [Related]
57. Filovirus infection of STAT-1 knockout mice.
Raymond J; Bradfute S; Bray M
J Infect Dis; 2011 Nov; 204 Suppl 3():S986-90. PubMed ID: 21987780
[TBL] [Abstract][Full Text] [Related]
58. Development of Prototype Filovirus Recombinant Antigen Immunoassays.
Boisen ML; Oottamasathien D; Jones AB; Millett MM; Nelson DS; Bornholdt ZA; Fusco ML; Abelson DM; Oda S; Hartnett JN; Rowland MM; Heinrich ML; Akdag M; Goba A; Momoh M; Fullah M; Baimba F; Gbakie M; Safa S; Fonnie R; Kanneh L; Cross RW; Geisbert JB; Geisbert TW; Kulakosky PC; Grant DS; Shaffer JG; Schieffelin JS; Wilson RB; Saphire EO; Branco LM; Garry RF; Khan SH; Pitts KR;
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S359-67. PubMed ID: 26232440
[TBL] [Abstract][Full Text] [Related]
59. A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.
Grant-Klein RJ; Van Deusen NM; Badger CV; Hannaman D; Dupuy LC; Schmaljohn CS
Hum Vaccin Immunother; 2012 Nov; 8(11):1703-6. PubMed ID: 22922764
[TBL] [Abstract][Full Text] [Related]
60. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
Suschak JJ; Schmaljohn CS
Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
